GlaxoSmithKline plc (GSK), Merck & Co. Inc. (MRK): HPV Vaccine for Boys Has “Good Start” in 1st Year

ATLANTA (AP) — When the HPV vaccine was first recommended for boys, health officials worried it would be an unusually hard sell. But a new report suggests that might not be the case.

About 1 in 5 boys got at least one of the recommended three doses last year, relatively good for a new vaccine aimed at adolescents.

The shots are largely intended not to protect boys from disease, but to stop them from spreading a sexually transmitted virus to girls that could cause cervical cancer.

The vaccine hasn’t been very popular among girls. The government report issued Thursday is the first real sense of how many boys are getting the shots.

“It’s a good start,” said Shannon Stokley, a vaccination expert with the Centers for Disease Control and Prevention.

According to the CDC, two HPV vaccines are licensed by the FDA and recommended by CDC. These vaccines are Cervarix (made by GlaxoSmithKline plc (LSE:GSK)) and Gardasil (made by Merck & Co., Inc. (NYSE:MRK)).

Introduced in 2006, the vaccine protects against human papillomavirus, which is spread during sex. Most infections go away on their own, without people developing symptoms. But the virus can cause cervical cancer in females, genital warts in both sexes, and some other, less common conditions like throat and anal cancer.

The vaccine was first recommended for girls ages 11 and 12 because it works best if given before a teen starts to have sex. In 2011, it was also recommended for boys that age to help prevent the virus’s spread.

The CDC report covers vaccination rates for last year, the first full year since the shots were advised for boys. It’s based on telephone calls to families for about 19,000 boys and girls ages 13 to 17.

About 21% of the boys had gotten at least one of the three doses. Less than 7% were fully vaccinated.

The rates look relatively good compared to the initial rates for some other vaccines aimed at adolescents. For example, the initial rate for a meningococcal vaccine was just 12%.

Rates tend to start low when a vaccine is first recommended and build after. So the HPV numbers for boys are reason to be optimistic, said the CDC’s Dr. Melinda Wharton, although she added a word of caution.

“Given how the coverage level has stalled for girls, though, a solid start isn’t enough,” she said.

For girls, the initial rate for at least one HPV shot was 25%. Last year, it was about 54% and hadn’t changed much from the previous two years. Only a third were fully immunized with all three doses last year.

“We’d really like to do much better with boys and girls,” Wharton said.

The article HPV Vaccine for Boys Has “Good Start” in 1st Year originally appeared on Fool.com is written by Associated Press.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.